SK12622002A3 - Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy - Google Patents

Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy Download PDF

Info

Publication number
SK12622002A3
SK12622002A3 SK1262-2002A SK12622002A SK12622002A3 SK 12622002 A3 SK12622002 A3 SK 12622002A3 SK 12622002 A SK12622002 A SK 12622002A SK 12622002 A3 SK12622002 A3 SK 12622002A3
Authority
SK
Slovakia
Prior art keywords
alkyl
carbon atoms
composition
cellulose acetate
glycogen phosphorylase
Prior art date
Application number
SK1262-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Dennis HOOVER
Ravi Mysore Shanker
Dwayne Thomas Friesen
Douglas Alan Lorenz
James Alan Schriver Nightingale
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SK12622002A3 publication Critical patent/SK12622002A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
SK1262-2002A 2000-03-16 2001-03-16 Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy SK12622002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (en) 2000-03-16 2001-03-16 Pharmaceutical compositions of glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
SK12622002A3 true SK12622002A3 (sk) 2004-02-03

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1262-2002A SK12622002A3 (sk) 2000-03-16 2001-03-16 Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy

Country Status (32)

Country Link
US (1) US20010053778A1 (sh)
EP (1) EP1263414A1 (sh)
JP (1) JP2003526654A (sh)
KR (1) KR20020081445A (sh)
CN (1) CN1418089A (sh)
AP (1) AP2002002621A0 (sh)
AR (1) AR027656A1 (sh)
AU (1) AU2001242669A1 (sh)
BG (1) BG107037A (sh)
BR (1) BR0109189A (sh)
CA (1) CA2403241A1 (sh)
CO (1) CO5280087A1 (sh)
CZ (1) CZ20022955A3 (sh)
EA (1) EA200200858A1 (sh)
EE (1) EE200200530A (sh)
HU (1) HUP0204583A2 (sh)
IL (1) IL151320A0 (sh)
IS (1) IS6508A (sh)
MA (1) MA26882A1 (sh)
MX (1) MXPA02009097A (sh)
NO (1) NO20024386L (sh)
OA (1) OA12232A (sh)
PA (1) PA8513601A1 (sh)
PE (1) PE20011184A1 (sh)
PL (1) PL360780A1 (sh)
SK (1) SK12622002A3 (sh)
SV (1) SV2002000343A (sh)
TN (1) TNSN01040A1 (sh)
TR (1) TR200202184T2 (sh)
WO (1) WO2001068055A1 (sh)
YU (1) YU67202A (sh)
ZA (1) ZA200207290B (sh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006402B1 (ru) * 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
HUP0400281A3 (en) 2001-06-22 2009-11-30 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
RU2278659C9 (ru) 2002-02-01 2007-02-20 Пфайзер Продактс Инк. Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1701704A2 (en) * 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN104755504A (zh) * 2012-08-24 2015-07-01 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
DK3725778T3 (da) 2012-09-11 2021-09-20 Medivation Prostate Therapeutics Llc Formuleringer af enzalutamid
EP3763702B1 (en) * 2013-07-19 2023-12-13 Siga Technologies, Inc. Preparation of amorphous tecovirimat dispersions
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
EP1263414A1 (en) 2002-12-11
IS6508A (is) 2002-08-16
NO20024386D0 (no) 2002-09-13
PL360780A1 (en) 2004-09-20
WO2001068055A1 (en) 2001-09-20
YU67202A (sh) 2006-01-16
HUP0204583A2 (hu) 2003-04-28
MA26882A1 (fr) 2004-12-20
CN1418089A (zh) 2003-05-14
AU2001242669A1 (en) 2001-09-24
IL151320A0 (en) 2003-04-10
CZ20022955A3 (cs) 2003-09-17
CA2403241A1 (en) 2001-09-20
BG107037A (bg) 2003-04-30
EA200200858A1 (ru) 2003-02-27
EE200200530A (et) 2004-04-15
CO5280087A1 (es) 2003-05-30
ZA200207290B (en) 2003-09-11
BR0109189A (pt) 2003-05-27
US20010053778A1 (en) 2001-12-20
JP2003526654A (ja) 2003-09-09
TR200202184T2 (tr) 2003-01-21
OA12232A (en) 2006-05-10
TNSN01040A1 (fr) 2005-11-10
AP2002002621A0 (en) 2002-09-30
KR20020081445A (ko) 2002-10-26
AR027656A1 (es) 2003-04-09
PA8513601A1 (es) 2004-08-31
NO20024386L (no) 2002-11-13
SV2002000343A (es) 2002-07-03
MXPA02009097A (es) 2003-03-12
PE20011184A1 (es) 2001-11-15

Similar Documents

Publication Publication Date Title
SK12622002A3 (sk) Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy
JP6932746B2 (ja) エンザルタミドの製剤
JP6192078B2 (ja) アピキサバン製剤
CA2582767C (en) Solid formulation with improved solubility and stability and method for producing said formulation
CN101048180B (zh) 具有改善的溶解度和稳定性的固体制剂和用于制备所述制剂的方法
ES2360064T3 (es) Dispersión sólida o preparación de dispersión sólida medicinal de un derivado de fenilalanina.
JP2022190168A (ja) グルコキナーゼ活性化剤およびppar受容体活性化剤を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用
JP4787446B2 (ja) グリブリド組成物
TW200821298A (en) Pharmaceutical compositions
EA028009B1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
KR100717570B1 (ko) 치료 효과를 신속하게 개시하는 시클로옥시게나제-2저해제 조성물
ES2366394T3 (es) Composiciones de eprosartán.
US20060167069A1 (en) Pharmaceutical composition of metaxalone with enhanced oral bioavailability
KR101441450B1 (ko) 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도
KR20090071829A (ko) 신장질환의 치료 및 예방을 위한 약제 조성물
WO2007102038A1 (en) Ziprasidone formulations
US20240216347A1 (en) Bezuclastinib formulations
RU2391099C2 (ru) Лекарственное средство, предназначенное для перорального введения, содержащее ингибитор циклооксигеназы-2, и способ его получения